CYP19A1 and breast cancer: Recently, everolimus (EVE) was also approved in combination with exemestane (EXE) for use in the USA and the 27 European Union member states, plus Iceland and Norway, and in Mexico, Argentina, and other Latin American countries, for the treatment of postmenopausal patients with HR+ breast cancer whose disease has progressed during or after nonsteroidal aromatase inhibitor therapy.